The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
PET sheets are widely recognised for their superior clarity, strength, and barrier properties
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
AI-powered cardiometabolic wellness platform for India’s workforce
Subscribe To Our Newsletter & Stay Updated
